Publications

GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST PROGRAM: ORIC-101

ORIC publications

An open-label Phase 1b study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster presented at: 2020 Genitourinary Cancers Symposium; February 13–15, 2020; San Francisco, CA, USA. Abstract #TPS253.
ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in TNBC
Poster presented at: 2019 San Antonio Breast Cancer Symposium; December 14, 2019; San Antonio, TX, USA. Abstract #2507.
ORIC-101 overcomes glucocorticoid-driven resistance to androgen receptor inhibition in CRPC
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A10.

CD73 INHIBITOR PROGRAM: ORIC-533

Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A19.